Incidence of and risk for osteonecrosis of the jaw in Korean osteoporosis patients treated with bisphosphonates: A nationwide cohort-study

被引:20
|
作者
Kim, Se Hwa [1 ]
Lee, Young-Kyun [2 ]
Kim, Tae-Young [3 ]
Ha, Yong-Chan [4 ]
Jang, Sunmee [5 ,6 ]
Kim, Ha Young [7 ,8 ]
机构
[1] Catholic Kwandong Univ, Int St Marys Hosp, Dept Internal Med, Coll Med, Incheon, South Korea
[2] Seoul Natl Univ, Bundang Hosp, Dept Orthopaed Surg, Seongnam, South Korea
[3] Konkuk Univ, Sch Med, Dept Orthopaed Surg, Seoul, South Korea
[4] Chung Ang Univ, Dept Orthopaed Surg, Coll Med, Seoul, South Korea
[5] Gachon Univ, Coll Pharm, Incheon, South Korea
[6] Gachon Univ, Gachon Inst Pharmaceut Sci, Incheon, South Korea
[7] Wonkwang Univ, Sanbon Hosp, Dept Internal Med, Coll Med, Gunpo, South Korea
[8] Univ Ulsan, Gangneung Asan Hosp, Dept Internal Med, Coll Med, Kangnung, South Korea
关键词
Bisphosphonates; Osteonecrosis of the jaw; Osteoporosis; Periodontal disease; SUPPRESSED BONE TURNOVER; ZOLEDRONIC ACID; POSTMENOPAUSAL OSTEOPOROSIS; RHEUMATOID-ARTHRITIS; ALENDRONATE; FRACTURES; WOMEN; ASSOCIATION; PREVALENCE;
D O I
10.1016/j.bone.2020.115650
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: To estimate the incidence of osteonecrosis of the jaw (ONJ) in patients treated with bisphosphonates (BPs) and to identify clinical risk factors that increase the risk for ONJ in Korean osteoporosis patients. Methods: We used data acquired from the Korean National Health Insurance Service. Among 2,140,149 participants with osteoporosis in 2012, we selected 164,926 new BP users and 164,926 ageand sex-matched control subjects. The control group included only patients with no prescriptions for BPs between January 1, 2011, and December 31, 2016. Participants were followed for 4 years. Results: Over the 4-year follow-up period, the cumulative incidence rates of ONJ were 20.9 and 6.9 per 100,000 person-years in the BP and control groups, respectively. The BP group had an increased risk for ONJ compared to the control group after adjusting for multiple variables (hazard ratio [HR] 3.72, 95% CI 2.70-5.11). Advanced age (>= 70 years), comorbid diseases such as diabetes, hypertension, and rheumatoid arthritis (RA) were independent risk factors for the development of ONJ. In addition, tooth extraction (HR 9.85), gingivitis, and periodontal disease (HR 4.78) were strongly associated with ONJ. Conclusions: ONJ incidence was 21 per 100,000 person-years in osteoporosis patients receiving bisphosphonates. Clinical factors including advanced age, diabetes, RA, dental disease, as well as BP use were significantly associated with ONJ.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid
    Dimopoulos, Meletios A.
    Kastritis, Efstathios
    Anagnostopoulos, Athanasios
    Melakopoulos, Ioannis
    Gika, Dimitra
    Moulopoulos, Lia A.
    Bamia, Christina
    Terpos, Evangelos
    Tsionos, Konstantinos
    Bamias, Aristotelis
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2006, 91 (07): : 968 - 971
  • [42] Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users
    Eiken, P. A.
    Prieto-Alhambra, D.
    Eastell, R.
    Abrahamsen, B.
    OSTEOPOROSIS INTERNATIONAL, 2017, 28 (10) : 2921 - 2928
  • [43] Osteonecrosis of the Jaw in Korean Woman with Osteoporosis Treated with Oral Bisphosphonate: Case Report
    Kong, Mi-Hee
    Baek, Kyung-Won
    Kim, Hyeon-Ju
    KOREAN JOURNAL OF FAMILY MEDICINE, 2008, 29 (07): : 520 - 524
  • [44] Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases
    Bramati, Annalisa
    Girelli, Serena
    Farina, Gabriella
    Dazzani, Maria Chiara
    Torri, Valter
    Moretti, Anna
    Piva, Sheila
    Dimaiuta, Mariastella
    La Verde, Nicla
    JOURNAL OF BONE AND MINERAL METABOLISM, 2015, 33 (01) : 119 - 124
  • [45] Risk factors for and incidence of osteoporosis in patients with breast cancer by gender : a nationwide cohort study
    Lee, Jin Ah
    Lee, Hye Sun
    Jeon, Soyoung
    Kim, Dooreh
    Lee, Youngjoo
    Bae, Sooyun
    Park, Woo-Chan
    Yoon, Chang Ik
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [46] Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients
    Gabbert, Tatjana I.
    Hoffmeister, Bodo
    Felsenberg, Dieter
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (04) : 749 - 758
  • [47] Treatment for osteoporosis and risk of osteonecrosis of the jaw among female patients in the United Kingdom Clinical Practice Research Datalink
    Persson, Rebecca
    Hagberg, Katrina Wilcox
    Pranschke, Emma
    Vasilakis-Scaramozza, Catherine
    Jick, Susan
    OSTEOPOROSIS INTERNATIONAL, 2025, 36 (01) : 47 - 60
  • [48] Preferences of Patients with Post-menopausal Osteoporosis Treated with Bisphosphonates - the VIVA II Study
    Payer, J.
    Cierny, D.
    Killinger, Z.
    Sulkova, I.
    Behuliak, M.
    Celec, P.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2009, 37 (04) : 1225 - 1229
  • [49] Prevalence of osteonecrosis of the jaw and oral characteristics of oncologic patients treated with bisphosphonates at the General Hospital of Mexico
    Veronica Cuevas-Gonzalez, Maria
    Minerva Diaz-Aguirre, Celia
    Echevarria-y-Perez, Enrique
    Carlos Cuevas-Gonzalez, Juan
    JOURNAL OF THE KOREAN ASSOCIATION OF ORAL AND MAXILLOFACIAL SURGEONS, 2016, 42 (06) : 365 - 369
  • [50] INTERDISCIPLINARY COOPERATION IN PREVENTIVE PROCEDURES OF OSTEONECROSIS OF THE JAW BONE IN PATIENTS TREATED WITH BISPHOSPHONATES
    Kovalova, Eva
    Klamrova, Tatiana
    Eliasova, Anna
    Novak, Bohuslav
    HEALTH PROBLEMS OF CIVILIZATION, 2015, 9 (04) : 49 - 53